BioSpace News Archive

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Diabetes Care, the peer-reviewed journal of the American Diabetes Association, has published a research paper on the company’s Phase 2 RELIEF-DPN-1 clinical trial investigating LX9211 for the treatment of diabetic peripheral neuropathic pain (DPNP).

Aurion Biotech today announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) Designation for AURN001, the Company’s allogeneic cell therapy candidate for the treatment of corneal edema secondary to corneal endothelial disease.

Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) – a commercial-stage medical technology company, today announced that it will host a webcast investor presentation on Tuesday, June 25, 2024 at 2:00 PM ET.

Ansys (NASDAQ: ANSS) today announced that it is adopting NVIDIA Omniverse application programming interfaces (APIs) to offer 3D-IC designers valuable insights from Ansys’ physics solver results through real-time visualization.

OSSIO, Inc. recently expanded its offering with the launch of OSSIOfiber® small compression staples for use in both hand and foot procedures, especially for bunion repair with a surgical technique known as the Akin osteotomy.

Toronto, Ontario--(Newsfile Corp. - June 19, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces...

announced that it has been awarded a Distribution Industry Award for Notable Achievement in Healthcare for “Best Overall Manufacturer, Branded Pharmaceuticals, Sales less than $300M” by the Healthcare Distribution Alliance.

Vanda Pharmaceuticals Inc. announced that the Company’s Board of Directors has determined that the unsolicited proposal from Cycle Group Holdings Ltd to acquire Vanda for $8.00 per share in cash and the revised unsolicited proposal from Future Pak, LLC to acquire Vanda for $8.50-$9.00 per share in cash plus certain Contingent Value Rights both substantially undervalue Vanda and are not in the best interests of the Company and its shareholders.

4WEB Medical, an orthopedic implant company focused on developing innovative implants that utilize its proprietary Truss Implant Technology™, announced the initial launch of the newest addition to the company’s portfolio, the Cervical Spine Truss System Integrated Plating Solution.

Theralase® Technologies Inc. is pleased to announce that it’s lead drug formulation, Rutherrin®, has demonstrated an ability to provide a complete response in a Non-Small Cell Lung Cancer animal model.